| Date | Title | | | 05/14/12 | Zogenix Reports First Quarter 2012 Financial Results|
Reiterates 2012 Financial Guidance
Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET
SUMAVEL(R) DosePro(R) (sumatriptan injection) Highlights
-- Total revenues of $18.3 million achieved in the first quarter 2012
-- Net product revenue increased to $9.9 million in the first quarter
2012, up 32% over the first quarter 2011
-- Contract revenue of
$8.5 million reflects final recognition of deferred revenue from
conc... |
|  | | 05/03/12 | Zogenix Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results| Conference Call Scheduled for May 14, 2012 at 4:30 pm ET
SAN DIEGO, May 3, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2012, after the market closes on Monday, May 14, 2012, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these finan... |
| | | 05/02/12 | Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro(TM) for Treatment of Chronic Pain| First NDA Submission for an Extended-Release Hydrocodone Therapy without Acetaminophen
SAN DIEGO, May 2, 2012 /PRNewswire via COMTEX/ --Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zohydro(TM) (hydrocodone bitartrate extended-release capsules), Zogenix's l... |
| | | 03/29/12 | Zogenix and Battelle Ink Marketing Agreement for DosePro(R) Drug Delivery Technology| Collaboration Opens Possibilities for New DosePro Applications That Offer Validated Needle-Free Subcutaneous Drug Delivery to Bio-Pharma Community
SAN DIEGO and COLUMBUS, Ohio, March 29, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and development organization, today finalized their previously announced ... |
| | | 03/08/12 | Zogenix Reports Fourth Quarter and Full Year 2011 Financial Results|
Conference Call and Webcast Today, March 8th, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Highlights
Increased total prescriptions to over 71,000 in 2011, a 104% increase over 2010*
Increased total prescriptions to over 21,000 in the fourth quarter 2011, 13% higher than the third quarter 2011 and 57% higher than fourth quarter 2010*
Maintained 39% refill rate for SUMAVEL DosePro in the fourth quarter*
Terminated the Astellas co-promotion agreement as of March 31, 2012; ... |
| | | 02/27/12 | Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2011 Financial Results| Conference Call Scheduled for March 8, 2012 at 4:30 pm ET
SAN DIEGO, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the fourth quarter and full year ended December 31, 2011, after the market closes on Thursday, March 8, 2012, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT)... |
| | | 02/10/12 | Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference| SAN DIEGO, Feb. 10, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President and Chief Operating Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at the Leerink Swann 2012 Global Healthcare Conference on February 16, 2012 in New York City.
Event: Leerink Swann 2012... |
| | | 01/25/12 | Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology| Includes Option for Joint Development of Expanded DosePro(R) Drug Delivery Platform
SAN DIEGO and COLUMBUS, Ohio, Jan. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and development organization, today announced a unique collaboration with the objective of advancing the development and commercialization... |
| |
|
